Please login to the form below

Not currently logged in
Email:
Password:

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

to complete its acquisition of gene therapy specialist Spark Therapeutics and its new blindness treatment Luxturna.

Latest news

  • Catalent preps for complex therapy boom with $1.2bn Paragon buy Catalent preps for complex therapy boom with $1.2bn Paragon buy

    Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to

  • Gyroscope advances gene therapy platform, merges with Orbit Gyroscope advances gene therapy platform, merges with Orbit

    Its chief investment officer, and chair of Gyroscope, Chris Hollowood said that the merge will allow Gyroscope to gain “all the platform capabilities it requires to develop and deliver its therapeutics ... Spark Therapeutics' Luxturna for inherited

  • Pfizer hedges bets on gene therapy deal Pfizer hedges bets on gene therapy deal

    Company not splashing out like Roche's Spark purchase. Pfizer has stopped short of joining 2019's gene therapy buying spree, instead acquiring a 15% of Vivet Therapeutics, and securing an ... In this way, the US pharma company is sidestepping the kind of

  • Biogen strikes $800m deal to buy gene therapy firm Nightstar Biogen strikes $800m deal to buy gene therapy firm Nightstar

    Nightstar Therapeutics. ... That includes Roche’s $4.3bn deal for Spark Therapeutics – which already sells a gene therapy for IRD called Luxturna – and Novartis’ takeover of AveXis for $8.7bn last year to

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    Can compete with rival Novartis in fast-developing area. Roche is set to transform its presence in advanced therapies with a $4.3bn deal to buy Spark Therapeutics, the first company ... Spark’s main location in Philadelphia will remain a “centre of

More from news
Approximately 11 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... of a more stable adeno-associated virus (AAV) – which now forms the basis of Spark Therapeutics’ drugs and,

  • Health on instalment Health on instalment

    For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

  • The rise of real-world evidence The rise of real-world evidence

    Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics